EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study

Zhen-Wei Shen, Ting-Han Jin, Kai-Qi Wu, Jie Zhao, Qi Jiang, Tong Guo, Liang Li, Xiao-Hua Feng, Pei-Pei Liu, Gui-Ling Chen iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70264 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Zhen-Wei Shen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Phase 1 Clinical Research Center, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzho…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allergic asthma, characterized by airborne allergen sensitivity and Th2 immune responses, is a common and increasing global health concern. Omalizumab, while effective, has limitations such as weight‐ and IgE‐dependent dosing regimens. JYB1904, a recombinant anti‐IgE humanized monoclonal antibody (IgG1 subtype), showed superior preclinical properties. We performed a single‐center, randomized, double‐blind, placebo‐controlled, single ascending‐dose phase Ia trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of JYB1904 in healthy adult participants across five dose levels (range: 75–600 mg; subcutaneously). JYB1904 was well tolerated, with no serious adverse events or safety concerns beyond those observed with omalizumab. Immunogenicity risk was low. PK analysis revealed approximately dose‐proportional parameters and an extended half‐life (2.5 times that of omalizumab). PD results showed significant free IgE suppression, with JYB1904 demonstrating stronger activity than omalizumab at equivalent doses. JYB1904 offers promising clinical advantages over omalizumab, including extended dosing intervals and enhanced efficacy, warranting further investigation for allergic asthma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAsthmaChinaDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersImmunoglobulin EInjections, SubcutaneousOmalizumabEast Asian People

Stichwörter der Autor:innen

JYB1904allergic asthmafree IgE suppressionpharmacodynamicspharmacokineticsphase Ia trial

Substanzen

Antibodies, Monoclonal, HumanizedImmunoglobulin EOmalizumab

Autor:innen und Institutionen

  • Department of Phase 1 Clinical Research Center, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, P. R. China.
  • Department of Phase 1 Clinical Research Center, Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) hospital, Shulan International Medical College, Zhejiang Shuren Univ…
  • Shanghai Jemincare Pharmaceutical co., Ltd., Shanghai, P. R. China.
  • Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P. R. China.

ORCID-Profile: Gui-Ling Chen

Zitieren

APA

Shen, Z. W., Jin, T. H., Wu, K. Q., Zhao, J., Jiang, Q., Guo, T., Li, L., Feng, X. H., Liu, P. P., & Chen, G. L. (2025). Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70264

Vancouver

Shen ZW, Jin TH, Wu KQ, Zhao J, Jiang Q, Guo T, et al. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study. Clinical and Translational Science. 2025. doi:10.1111/cts.70264

BibTeX
@article{Shen2025,
  author = {Shen, Zhen-Wei and Jin, Ting-Han and Wu, Kai-Qi and Zhao, Jie and Jiang, Qi and Guo, Tong and Li, Liang and Feng, Xiao-Hua and Liu, Pei-Pei and Chen, Gui-Ling},
  title = {Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70264}
}
Kostenlos starten →